|Articles|August 1, 2004

Antiandrogen/castration may reduce death risk by 20%

New Orleans--Bicalutamide (Casodex), 50 mg, plus castration leads to an estimated 20% reduction in risk of prostate cancer death versus castration alone, according to results of a historical data analysis presented at the annual of the American Society of Clinical Oncology meeting here.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.


Latest CME